Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 30
- Registration Number
- NCT05011487
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2021-08-12
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT05001880
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Carle at The Riverfront, Danville, Illinois, United States
A Study of SEA-CD40 Given With Other Drugs in Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT04993677
- Locations
- 🇺🇸
Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Allina Health Cancer Institute, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04991025
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
- Conditions
- Interventions
- Biological: AtezolizumabProcedure: BiopsyProcedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyDrug: CisplatinDrug: EtoposideRadiation: External Beam Radiation TherapyProcedure: Magnetic Resonance ImagingDrug: PaclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT04989283
- Locations
- 🇺🇸
Community Medical Hospital, Missoula, Montana, United States
🇺🇸The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸Rush - Copley Medical Center, Aurora, Illinois, United States
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Dr Joanne CHIU
- Target Recruit Count
- 46
- Registration Number
- NCT04989322
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
- Conditions
- Interventions
- First Posted Date
- 2021-08-03
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 776
- Registration Number
- NCT04988295
- Locations
- 🇳🇱
VUMC Amsterdam, Amsterdam, Netherlands
🇲🇽Instituto Nacional de Cancerologia, Mexico, Mexico
🇲🇽Oncologia Integral Satelite, Naucalpan, Mexico
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
- Conditions
- Metastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage IIIC Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Unresectable Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
- Interventions
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT04971187
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Using ctDNA to Determine Therapies for Lung Cancer
- First Posted Date
- 2021-07-19
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 66
- Registration Number
- NCT04966663
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Pembro+Chemo in Brain Mets
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- John L. Villano, MD, PhD
- Target Recruit Count
- 3
- Registration Number
- NCT04964960
- Locations
- 🇺🇸
University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.